DailySand tracks FDA across AI, semiconductor infrastructure, capital markets, and critical minerals supply chains. Below are curated source items and daily digests where FDA appears in today's cross-sector intelligence briefing.
2 items across 2 digests
The FDA selected Eli Lilly and Regeneron among seven initial companies for its PreCheck Pilot Program to accelerate manufacturing facility reviews. Streamlined facility approval processes reduce time-to-market for pharmaceutical manufacturing expansions, particularly relevant for biotech supply chain scaling.
Read original →FDA approves leucovorin as the first drug treatment for a rare genetic disorder, following previous promotion by the Trump administration as a potential autism therapy. This regulatory approval could establish a precedent for broader neurological applications and represents a significant milestone in rare disease treatment development.
Read original →
DailySand